Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial

Laryngoscope

Volumn 123, Issue 6, 2013, Pages 1334-1340

  Wang, De Hui ^a   Chen, Lei ^b   Cheng, Lei ^b   Li, Ke Nan ^a   Yuan, Hu ^b   Lu, Ji Hong ^c   Li, Han ^a  

^a FUDAN UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Dermatophagoides farinae; Dermatophagoides pteronyssinus; efficacy; house dust mite; serum sIgE; serum sIgG4; Sublingual immunotherapy

Indexed keywords

HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LORATADINE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLERGIC RHINITIS; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL PRURITUS; NOSE OBSTRUCTION; ORAL PRURITUS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SIDE EFFECT; SNEEZING; SUBLINGUAL IMMUNOTHERAPY; SWELLING; THIRST; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ALLERGENS; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, DERMATOPHAGOIDES; CHILD; CHILD, PRESCHOOL; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; RHINITIS, ALLERGIC, PERENNIAL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878143522     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23935     Document Type: Article

References (37)

1. Platts-Mills TAE, De Weck AL,. Dust mite allergens and asthma-a worldwide problem. J Allergy Clin Immunol 1989; 83: 416-427.
2. Gelber LE, Seltzer LH, Bouzoukis JK, Pollart SM, Chapman MD, Platts-Mills TAE,. Sensitization and exposure to indoor allergens as risk factors for asthma among patients presenting to hospital. Am J Respir Crit Care Med 1993; 147: 573-578.
3. Sporik R, Chapman MD, Platts-Mills TAE,. House dust mite exposure as a cause of asthma. Clin Exp Allergy 1992; 22: 897-906.
4. Jonathan C,. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99: S781-S786.
5. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B,. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994; 94: 182-188.
6. Thompson AK, Juniper E, Meltzer EO,. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000; 85: 338-348.
7. Sub-lingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64: 1-59.
8. Wen CJ, Zhu MF, Ren WM, Liu XY, Qian H,. Clinical efficacy and safety of sublingual immunotherapy using standardized dermatophagoides farinae extract for children with combined allergic rhinitis and asthma syndrome. Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2011; 46: 393-396.
9. Zuwang L, Yu X, Zezhang T, Wanyi C, Ailing D, Yonggang K,. Sublingual immunotherapy with a standardized dermatophagoides farinae extract for allergic rhinitis. Chinese Archives of Otolaryngology-Head and Neck Surgery 2010; 17: 3-6.
10. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-334.
11. Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Méchin H, Daures JP, Bousquet J., Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007; 62: 367-372.
12. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy 2008; 63: 8-160.
13. Mailing HJ, Weeke B,. Position Paper: Immunotherapy. Allergy 1993; 48: 9-35.
14. Lombardi C, Incorvaia C, Braga M, Senna G, Canonica GW, Passalacqua G,. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy 2009; 64: 849-854.
15. Incorvaia C, Mauro M, Ridolo E, Puccinelli P, Liuzzo M, Scurati S, Frati F,. Patient's compliance with allergen immunotherapy. Patient Prefer Adherence 2008; 2: 247-251.
16. Passalacqua G, Compalati E, Canonica GW,. Sublingual immunotherapy for allergic rhinitis: an update. Curr Opin Otolaryngol Head Neck Surg 2011; 19: 43-47 10.1097/MOO.0b013e328341d0bd.
17. Wilson DR, Torres Lima M, Durham SR,. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60: 4-12.
18. Bush RK, Swenson C, Fahlberg B, Evans MD, Esch R, Busse WW,. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011; 127: 974-981.e7.
19. Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F,. Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005; 60: 952-956.
20. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S,. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802-809.
21. Bordignon V, Parmiani S,. Variation of the skin end-point in patients treated with sublingual specific immunotherapy. J Investig Allergol Clin Immunol 2003; 13: 170-176.
22. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS,. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117: 1,021-1,035.
23. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, Till SJ,. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121: 1120-1125.e2.
24. Fujimura T, Okamoto Y, Taniguchi M,. Therapeutic effects and biomarkers in sublingual immunotherapy: a review. J Allergy (Cairo) 2012; 2012: 381737. Epub 2012.
25. Guez S, Vatrinet C, Fadel R, Andre C,. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000; 55: 369-375.
26. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, Delecluse P, Andre C,. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59: 491-497.
27. Marcucci F, Sensi L, Di Cara G, Salvatori S, Bernini M, Pecora S, Burastero SE,. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol 2005; 16: 519-526.
28. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L,. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61: 151-165.
29. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW,. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990; 86: 521-531.
30. Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33: 1198-1208.
31. Piazza I, Bizzaro N,. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy 1993; 71: 461-469.
32. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-γ- and interleukin-10- production. Clin Exp Allergy 2006; 36: 261-272.
33. Incorvaia C, Mauro M, Ridolo E, Puccinelli P, Liuzzo M, Scurati S, Frati F,. Patient's compliance with allergen immunotherapy. Patient Prefer Adherence 2008; 2: 247-251.
34. Passalacqua G, Canonica GW,. Sublingual immunotherapy for allergic respiratory diseases: efficacy and safety. Immunol Allergy Clin North Am 2011; 31: 265-277.
35. Andre C, Perrin-Fayolle M, Grosclaude M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol 2003; 131: 111-118.
36. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ,. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59: 45-53.
37. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G,. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003; 33: 1641-1647.